ABSTRACT
Solid organ transplant recipients are particularly susceptible to Merkel cell carcinoma (MCC) as a result of their iatrogenic immunosuppression in order to prevent graft failure. This group of individuals are known to develop MCC at a younger age and have worse outcomes from their disease. Early diagnosis, aggressive treatment, and modification of immunosuppression are all critical to improving outcomes in these patients. Increasing research and developing individualized therapies for MCC in solid organ transplant recipients is crucial to optimizing the management of these patients.
